Please try another search
DongKook Pharmaceutical Co., Ltd. produces and sell pharmaceutical products in South Korea and internationally. The company offers non-prescription and prescription drugs, quasi drugs, medical devices, active pharmaceutical ingredients, and cosmetics. Its pipeline includes DKF-310, which is in preclinical trials for the treatment of dementia; DKM-413, used for anesthetic; DKF-361, used to treat hypertension; DKF-325, an anticoagulant; DKM-412 and DKM-420 to treat osteoarthritis; DKF-313, that is in clinical studies, indicated for benign prostatic hyperplasia; DKF-340, a nonsteroidal anti-inflammatory drugs; DKM-415, indicated for synovial fluid replacement; DKF-334 and DKF-335 to treat osteoporosis; and DKF-363, for treatment of respiratory inflammation. In addition, the company develops DKB-119 and DKM-410, a biomaterial for tissue restoration; as well as develops new drugs for obesity and diabetes that is in preclinical studies. The company was formerly known as UEC & Co., Ltd. and changed its name to DongKook Pharmaceutical Co., Ltd. in March 1982. The company was founded in 1968 and is headquartered in Seoul, South Korea.
Name | Age | Since | Title |
---|---|---|---|
Gi-Beom Kwon | 57 | - | Vice Chairperson |
Min-Gu Lee | 57 | - | Outside Director |
Young-Wook Lee | 71 | - | CEO, President & Director |
Jae-Sung Gu | 62 | - | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review